Neuralstem, Inc. (NASDAQ:CUR) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

Separately, S&P Equity Research decreased their price objective on Neuralstem from $3.69 to $3.18 in a report on Thursday, February 16th.

Shares of Neuralstem (NASDAQ CUR) traded down 3.0263% on Friday, hitting $5.1687. 88,538 shares of the stock traded hands. The stock’s 50 day moving average price is $4.59 and its 200 day moving average price is $3.47. Neuralstem has a 52-week low of $2.47 and a 52-week high of $6.19. The stock’s market cap is $61.50 million.

ILLEGAL ACTIVITY WARNING: “Neuralstem, Inc. (CUR) Rating Increased to Hold at ValuEngine” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/06/09/neuralstem-inc-cur-rating-increased-to-hold-at-valuengine.html.

In other news, CEO Richard J. Daly acquired 7,500 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was acquired at an average cost of $4.00 per share, with a total value of $30,000.00. Following the completion of the acquisition, the chief executive officer now owns 23,312 shares of the company’s stock, valued at $93,248. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jones Jonathan Brian Lloyd acquired 5,455 shares of the firm’s stock in a transaction dated Friday, March 24th. The stock was purchased at an average cost of $5.50 per share, with a total value of $30,002.50. Following the completion of the acquisition, the chief financial officer now directly owns 7,859 shares of the company’s stock, valued at approximately $43,224.50. The disclosure for this purchase can be found here. 19.25% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in Neuralstem stock. Alethea Capital Management LLC purchased a new stake in Neuralstem, Inc. (NASDAQ:CUR) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 164,394 shares of the company’s stock, valued at approximately $868,000. Alethea Capital Management LLC owned about 1.49% of Neuralstem as of its most recent SEC filing.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.